Ceruloplasmin serum concentrations in a large randomized population sample;Serumcoeruloplasmin in einer randomisierten bevölkerungsstichprobe mit 2 445 probanden

Nervenheilkunde

Volumn 30, Issue 8, 2011, Pages 555-561

  Gedack, M ^a   Hanle M M ^a   Schonfeldt Lecuona C ^a   Kratzer, W ^a,b   Kassubek, J ^a   Brummer, D ^a   Connemann, Bernard J ^a   Adler, G ^b   Armsen, A ^b   Banzhaf, H M ^b   Bauerdick, M ^b   Bertling, U ^b   Boehm, B O ^b   Brandner, B O ^b   Brockmann, S O ^b   Deckert, M ^b   Dingler, C ^b   Eggink, S ^b   Fuchs, M ^b   Gaus, W ^b   Goussis, H ^b   Gruenert, A ^b   Haenle, M M ^b   Hampl, W ^b   Haug, C ^b   Hay, B ^b   Huetter, M L ^b   Imhof, A ^b   Kern, P ^b   Kimmig, P ^b   Kirch, A ^b   Klass, D ^b   Koenig, W ^b   Kron, M ^b   Manfras, B ^b   Meitinger, K ^b   Mertens, T ^b   Oehme, R ^b   Pfaff, G ^b   Piechotowski, I ^b   Reuter, S ^b   Romig, T ^b   Von Schmiesing, A F A ^b   Steinbach, G ^b   Tourbier, M ^b   Voegtle, A ^b   Walcher, T ^b   Wolff, S ^b   more..

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b Klinik für Psychiatrie und Psychotherapie III ^*

Author keywords

Brain diseases; Heredodegenerative disorders; Inborn errors; Metabolism; Metal metabolism; Neurobehavioral manifestations

Indexed keywords

BIOLOGICAL MARKER; CERULOPLASMIN; CHOLESTEROL;

ARTICLE; CERULOPLASMIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; IMMUNOCHEMISTRY; IMMUNONEPHELOMETRY; INFLAMMATION; NEPHELOMETRY; ORAL CONTRACEPTION; POPULATION RESEARCH; SEX DIFFERENCE;

EID: 80052639956     PISSN: 07221541     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1628394     Document Type: Article

References (38)

1. Abood LG, Gibbs FA, Gibbs E. Comparative study of blood ceruloplasmin in schizophrenia and other disorders. AMA Arch Neurol Psychiatr 1957; 77: 643-5.
2. Akerfeldt S. Oxidation of N, N-dimethyl-p-phenylenediamine by serum from patients with mental disease. Science 1957; 125(3238): 117-9.
3. Bock E, Weeke B, Rafaelsen OJ. Serum proteins in acutely psychotic patients. J Psychiatr Res 1971; 9: 1-9.
4. Boehm BO et al. Prevalence of the metabolic syndrome in southwest Germany. Scand J ClinLab Invest Suppl 2005; 240: 122-8.
5. Connemann BJ et al. Die Bedeutung des Serum-Coeruloplasmins für die Differentialdiagnose neuropsychiatrischer Störungen. Fortschr Neurol Psychiatr 2010; 78: 582-9.
6. Cox DW. Factors influencing serum ceruloplasmin levels in normal individuals. J Lab Clin Med 1966; 68: 893-904.
7. Ganrot PO. Variation of the concentrations of some plasma proteins in normal adults, in pregnant women and in newborns. Scand J Clin Lab Invest Suppl 1972; 124: 83-8.
8. Gregg XT, Reddy V, Prchal JT. Copper deficiency masquerading as myelodysplastic syndrome. Blood 2002; 100: 1493-5. (Pubitemid 34864311)
9. Harris ZL, Durley AP, Man TK, Gitlin JD. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. Proc Natl Acad Sci USA 1999; 96: 10812-7. (Pubitemid 29442226)
10. Harris ZL. Not all absent serum ceruloplasmin is Wilson disease: a review of aceruloplasminemia. J Investig Med 2002; 50: 236-8.
11. Heilmeyer L, Keiderling W, Struve C. Kupfer und Eisen als körpereigne Wirkstoffe und ihre Bedeutung beim Krankheitsgeschehen. Jena: Fischer 1941.
12. Hellman NE, Gitlin JD. Ceruloplasmin metabolism and function. Annu Rev Nutr 2002; 22: 439-58.
13. Holmberg CG, Laurell CB. Investigations in serum copper. II. Isolation of the copper-containing protein and a description of some of its properties. Acta Chem Scand 1948; 2: 550-6.
14. Ichihara K, Kawai T. Determination of reference intervals for 13 plasma proteins based on IFCC international reference preparation [CRM470] and NCCLS proposed guideline [C28-P,1992]: trial to select reference individuals by results of screening tests and application of maximal likelihood method. J Clin Lab Anal 1996; 10: 110-7.
15. Kaneko K et al. Astrocytic deformity and globular structures are characteristic of the brains of patients with aceruloplasminemia. J Neuropathol Exp Neurol 2002; 61: 1069-77. (Pubitemid 35435025)
16. Kono S, Miyajima H. Molecular and pathological basis of aceruloplasminemia. Biol Res 2006; 39: 15-23.
17. Koschinsky ML et al. Complete cDNA sequence of human preceruloplasmin. Proc Natl Acad Sci USA 1986; 83: 5086-90. (Pubitemid 16051321)
18. Kumar N et al. Copper deficiency myelopathy. Arch Neurol 2004; 61: 762-6.
19. Lehmann HP, Schosinsky KH, Beeler MF. Standardization of serum ceruloplasmin concentrations in international enzyme units with o-dianisidinedihydrochloride as substrate. Clin Chem 1974; 20: 1564-7.
20. Markowitz H et al. Studies on copper metabolism. XIV. Copper, ceruloplasmin and oxidase activity in sera of normal human subjects, pregnant women, and patients with infection, hepatolenticular degeneration, and the nephritic syndrome. J Clin Invest 1955; 34: 1498-508.
21. Martens S, Valbo S, Melander B. Studies on the role of ceruloplasmin in schizophrenia. Acta psych neurol scand 1959; 34 Suppl 136: 349-60.
22. Meyer LA et al. Copper transport and metabolism are normal in aceruloplasminemic mice. J Biol Chem 2001; 276: 36857-61.
23. Miyajima H et al. Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration. Neurology 1987; 37: 761-7. (Pubitemid 17064662)
24. Miyajima H. Aceruloplasminemia, an iron metabolic disorder. Neuropathology 2003; 23: 345-50.
25. Morell AG et al. Measurement of concentration of ceruloplasmin in serum by determination of its oxidase activity. In: Sunderman FW, Sunderman FW Jr, (Hrsg.). Laboratory diagnosis of liver diseases. St Louis: Greene 1968.
26. Olantunbosun D et al. Serum copper in schizophrenia in Nigerians. Br J Psychiatry 1975; 127: 119-21.
27. Osaki S, Johnson DA, Frieden E. The possible significance of the ferrous oxidase activity of ceruloplasmin in normal human serum. J Biol Chem 1966; 241: 2746-51.
28. Rahman B, Rahman MA, Hassan Z. Variation of copper and ceruloplasmin levels with liver function tests in schizophrenic patients. Biomedicine 1978; 29: 238-41. (Pubitemid 9104792)
29. Scheinberg I. Ceruloplasmin test for Wilson's disease. Pediatrics 1963; 31: 160-1.
30. Scheinberg IH, Gitlin D. Deficiency of ceruloplasmin in patients with hepatolenticular degeneration [Wilson's disease]. Science 1952; 116(3018): 484-5.
31. Scheinberg IH et al. Concentration of ceruloplasmin in plasma of schizophrenic patients. Science 1957; 126(3279): 925-6.
32. Schosinsky KH, Lehmann HP, Beeler MF. Automated determination of serum ceruloplasmin activity with o-dianisidine dihydrochloride as substrate. Clin Chem 1975; 21: 757-9.
33. Secchi GC, Petrella A, Lomanto B, Gervasini N. Ceruloplasmin activity in liver diseases. Quantitative determination and electrophoretic characterization. Enzym biol clin 1967; 8; 33-41.
34. Störiko K. Normal values for 23 different human plasma proteins determined by single radial immunodiffusion. Blut 1968; 16; 200-8.
35. Sunderman FW, Nomoto S. Measurement of human serum ceruloplasmin by its p-phenylenediamine oxidase activity. Clin Chemistry 1970; 16; 903-10.
36. Weiss WA. Normalwerte spezifischer Serumproteine im Kindes- und Erwachsenenalter. Klin Wochenschr 1965; 43: 273-7.
37. Wilson SAK. Progressive lenticular degeneration: a familial nervous system disease associated with cirrhosis of the liver. Brain 1912; 34: 295-509.
38. Yunice AA, Lindeman RD, Czerwinski AW, Clark M. Influence of age and sex on serum copper and ceruloplasmin levels. J Gerontol 1974; 29: 277-81.